GlassScriptPhysician profile
Meghan Heald
NPI 1447861281
$8,325.47
in general payments reported to CMS, 2019-2025
47 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,989 · 2022: $1,846 · 2023: $2,773 · 2024: $1,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,391 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,390.70 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,776.50 | 2021-2024 | |
| Novo Nordisk INC | $562.61 | 2021-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $522.40 | 2021-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $497.36 | 2021-2024 | Repatha, Otezla, Prolia |
| Corium, LLC | $454.35 | 2022-2024 | Azstarys |
| Pfizer INC. | $449.00 | 2021-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $349.19 | 2021-2023 | Cuvitru |
| Astellas Pharma US INC | $298.83 | 2021-2023 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $277.64 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $262.65 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $258.48 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $235.98 | 2021-2024 | Rexulti, Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $220.34 | 2022-2024 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $211.84 | 2021-2024 | Breztri |
| Idorsia Pharmaceuticals US INC | $144.42 | 2023 | Quviviq |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Heald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.